AR018186A1 - Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto - Google Patents
Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuestoInfo
- Publication number
- AR018186A1 AR018186A1 ARP990101770A ARP990101770A AR018186A1 AR 018186 A1 AR018186 A1 AR 018186A1 AR P990101770 A ARP990101770 A AR P990101770A AR P990101770 A ARP990101770 A AR P990101770A AR 018186 A1 AR018186 A1 AR 018186A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- spla2
- carbazoly
- tetrahydrocarbazol
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 abstract 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se trata de nuevos compuestos tricíclicos de aplicacion en la inhibicion de la liberacion de ácidos grasos mediada por sPLA2, tal como el choque séptico.Dichos compuestos responden a las formulas (I) y (II) donde: Z es ciclohexenilo o fenilo; R21 esun sustituyente no interferente; R21 es un grupo -NHNH2 y R2es un grupo hidroxilo o -O(CH2)mR5, donde R5 tiene los valores indicados en la descripcion. También se reivindican los objetivos mencionados en el título de lasolicitud.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6232898A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018186A1 true AR018186A1 (es) | 2001-10-31 |
Family
ID=22041763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101770A AR018186A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto |
| ARP990101771A AR018593A1 (es) | 1998-04-17 | 1999-04-16 | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101771A AR018593A1 (es) | 1998-04-17 | 1999-04-16 | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP0950657B1 (es) |
| JP (2) | JP4435330B2 (es) |
| KR (2) | KR100586761B1 (es) |
| CN (1) | CN1149193C (es) |
| AR (2) | AR018186A1 (es) |
| AT (2) | ATE268756T1 (es) |
| AU (2) | AU753436B2 (es) |
| BR (2) | BR9901279A (es) |
| CA (2) | CA2269262A1 (es) |
| CO (2) | CO5031247A1 (es) |
| CZ (2) | CZ136999A3 (es) |
| DE (2) | DE69918590T2 (es) |
| DK (1) | DK0950657T3 (es) |
| DZ (1) | DZ2769A1 (es) |
| EA (2) | EA002816B1 (es) |
| ES (2) | ES2226286T3 (es) |
| HU (2) | HUP9901221A3 (es) |
| ID (2) | ID23761A (es) |
| IL (2) | IL129485A0 (es) |
| NO (2) | NO312240B1 (es) |
| NZ (3) | NZ335253A (es) |
| PE (2) | PE20000432A1 (es) |
| PL (2) | PL332566A1 (es) |
| PT (1) | PT950657E (es) |
| SG (2) | SG81976A1 (es) |
| SI (1) | SI0950657T1 (es) |
| TR (2) | TR199900843A2 (es) |
| TW (1) | TWI238160B (es) |
| YU (2) | YU18999A (es) |
| ZA (2) | ZA992771B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610728B2 (en) * | 1997-08-28 | 2003-08-26 | Eli Lilly And Company | Method for treatment of non-rheumatoid arthritis |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| EP1214041A2 (en) * | 1998-12-21 | 2002-06-19 | Eli Lilly And Company | Combination therapy for the treatment of sepsis |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| JP2003505372A (ja) * | 1999-07-19 | 2003-02-12 | イーライ・リリー・アンド・カンパニー | ｓＰＬＡ２インヒビター |
| AU2001267826A1 (en) * | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for alzheimer's disease |
| AU2001267825A1 (en) | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for cirrhosis |
| AU2001267824A1 (en) * | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for cancer |
| WO2002005796A2 (en) * | 2000-07-14 | 2002-01-24 | Eli Lilly And Company | Use of a spla2 inhibitor for the treatment of sepsis |
| CA2431028A1 (en) | 2000-12-18 | 2002-06-27 | Ho-Shen Lin | Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| US6933313B2 (en) | 2001-03-28 | 2005-08-23 | Eli Lilly And Company | Substituted carbazoles as inhibitors of sPLA2 |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| DE10249055A1 (de) | 2002-10-22 | 2004-05-06 | Bayer Cropscience Ag | 2-Phenyl-2-substituierte-1,3-diketone |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| AU2009230127B2 (en) | 2008-03-26 | 2011-12-22 | Daiichi Sankyo Company, Limited | Novel tetrahydroisoquinoline derivative |
| PE20091838A1 (es) | 2008-04-09 | 2009-12-18 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de acido graso |
| EP2379538A4 (en) * | 2009-01-22 | 2013-01-02 | Orchid Res Lab Ltd | HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER |
| JP2012523425A (ja) | 2009-04-07 | 2012-10-04 | インフイニトイ プハルマセウトイカルス インコーポレイテッド | 脂肪酸アミドヒドロラーゼの阻害薬 |
| CA2757679A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| RU2569061C2 (ru) | 2010-02-03 | 2015-11-20 | Инфинити Фармасьютикалз, Инк. | Ингибиторы амид-гидролазы жирных кислот |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102816107B (zh) * | 2012-08-20 | 2015-06-03 | 东南大学 | 咔唑衍生物及其制备方法与用途 |
| CA2889642A1 (en) * | 2012-11-30 | 2014-06-05 | Ge Healthcare Limited | Zinc halide mediated cyclization process leading to tricyclic indoles |
| WO2014083113A1 (en) | 2012-11-30 | 2014-06-05 | Ge Healthcare Limited | Crystallization process of tricyclic indole derivatives |
| EP3248230B1 (de) * | 2015-01-20 | 2020-05-06 | cynora GmbH | Verwendung organischer moleküle in optoelektronischen bauelementen |
| CN108707104A (zh) * | 2018-08-07 | 2018-10-26 | 北京恒信卓元科技有限公司 | 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579534A (en) * | 1969-05-09 | 1971-05-18 | American Cyanamid Co | Tetrahydrocarbazolecarboxylates |
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| WO1993001169A2 (en) * | 1991-07-05 | 1993-01-21 | Merck Sharp & Dohme Limited | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| CA2179678A1 (en) * | 1995-06-23 | 1996-12-24 | Michael Edward Flaugh | 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles |
| HUP9901984A3 (en) * | 1995-12-13 | 2001-01-29 | Lilly Co Eli | Naphthyl acetamides as spla2 inhibitors, use thereof and pharmaceutical compositions containing these compounds |
| BR9713261A (pt) * | 1996-10-30 | 2000-03-28 | Lilly Co Eli | Tricìclicos substituìdos |
| CA2304482A1 (en) * | 1997-09-26 | 1999-04-08 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
| WO1999025340A1 (en) * | 1997-11-14 | 1999-05-27 | Eli Lilly And Company | Treatment for alzheimer's disease |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
-
1999
- 1999-04-14 DZ DZ990069A patent/DZ2769A1/xx active
- 1999-04-15 IL IL12948599A patent/IL129485A0/xx unknown
- 1999-04-15 ID IDP990341D patent/ID23761A/id unknown
- 1999-04-15 ID IDP990340D patent/ID23287A/id unknown
- 1999-04-15 IL IL12948399A patent/IL129483A0/xx unknown
- 1999-04-16 TR TR1999/00843A patent/TR199900843A2/xx unknown
- 1999-04-16 AU AU23817/99A patent/AU753436B2/en not_active Ceased
- 1999-04-16 KR KR1019990013438A patent/KR100586761B1/ko not_active Expired - Fee Related
- 1999-04-16 ZA ZA9902771A patent/ZA992771B/xx unknown
- 1999-04-16 CO CO99022884A patent/CO5031247A1/es unknown
- 1999-04-16 DK DK99302967T patent/DK0950657T3/da active
- 1999-04-16 CN CNB991079574A patent/CN1149193C/zh not_active Expired - Fee Related
- 1999-04-16 NZ NZ335253A patent/NZ335253A/xx unknown
- 1999-04-16 PT PT99302967T patent/PT950657E/pt unknown
- 1999-04-16 CA CA002269262A patent/CA2269262A1/en not_active Abandoned
- 1999-04-16 YU YU18999A patent/YU18999A/sh unknown
- 1999-04-16 HU HU9901221A patent/HUP9901221A3/hu unknown
- 1999-04-16 SG SG9901681A patent/SG81976A1/en unknown
- 1999-04-16 PL PL99332566A patent/PL332566A1/xx not_active Application Discontinuation
- 1999-04-16 ES ES99302967T patent/ES2226286T3/es not_active Expired - Lifetime
- 1999-04-16 AT AT99302941T patent/ATE268756T1/de not_active IP Right Cessation
- 1999-04-16 AR ARP990101770A patent/AR018186A1/es not_active Application Discontinuation
- 1999-04-16 SI SI9930650T patent/SI0950657T1/xx unknown
- 1999-04-16 CZ CZ991369A patent/CZ136999A3/cs unknown
- 1999-04-16 TR TR1999/00853A patent/TR199900853A2/xx unknown
- 1999-04-16 YU YU19199A patent/YU19199A/sh unknown
- 1999-04-16 NO NO19991822A patent/NO312240B1/no not_active IP Right Cessation
- 1999-04-16 DE DE69918590T patent/DE69918590T2/de not_active Expired - Lifetime
- 1999-04-16 EA EA199900303A patent/EA002816B1/ru not_active IP Right Cessation
- 1999-04-16 ZA ZA9902772A patent/ZA992772B/xx unknown
- 1999-04-16 SG SG9901869A patent/SG81977A1/en unknown
- 1999-04-16 EP EP99302967A patent/EP0950657B1/en not_active Expired - Lifetime
- 1999-04-16 NO NO19991821A patent/NO314400B1/no not_active IP Right Cessation
- 1999-04-16 PL PL99332565A patent/PL332565A1/xx not_active Application Discontinuation
- 1999-04-16 JP JP15240099A patent/JP4435330B2/ja not_active Expired - Fee Related
- 1999-04-16 AR ARP990101771A patent/AR018593A1/es active IP Right Grant
- 1999-04-16 HU HU9901220A patent/HUP9901220A3/hu unknown
- 1999-04-16 JP JP11109629A patent/JPH11322713A/ja not_active Withdrawn
- 1999-04-16 AU AU23819/99A patent/AU753547B2/en not_active Ceased
- 1999-04-16 BR BR9901279-0A patent/BR9901279A/pt not_active IP Right Cessation
- 1999-04-16 TW TW088106130A patent/TWI238160B/zh not_active IP Right Cessation
- 1999-04-16 CZ CZ991370A patent/CZ137099A3/cs unknown
- 1999-04-16 AT AT99302967T patent/ATE271037T1/de active
- 1999-04-16 PE PE1999000314A patent/PE20000432A1/es not_active Application Discontinuation
- 1999-04-16 KR KR1019990013436A patent/KR19990083232A/ko not_active Withdrawn
- 1999-04-16 EA EA199900301A patent/EA002347B1/ru not_active IP Right Cessation
- 1999-04-16 ES ES99302941T patent/ES2222663T3/es not_active Expired - Lifetime
- 1999-04-16 DE DE69917833T patent/DE69917833T2/de not_active Expired - Lifetime
- 1999-04-16 PE PE1999000320A patent/PE20000476A1/es not_active Application Discontinuation
- 1999-04-16 CA CA002269246A patent/CA2269246C/en not_active Expired - Fee Related
- 1999-04-16 CO CO99022897A patent/CO5011054A1/es unknown
- 1999-04-16 EP EP99302941A patent/EP0952149B1/en not_active Expired - Lifetime
- 1999-04-16 BR BR9902365-2A patent/BR9902365A/pt not_active IP Right Cessation
- 1999-04-16 NZ NZ335251A patent/NZ335251A/xx unknown
- 1999-04-16 NZ NZ507564A patent/NZ507564A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018186A1 (es) | Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto | |
| ES2139943T3 (es) | Nuevos inhibidores de la sintasa de prostaglandina. | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| UY25204A1 (es) | Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos | |
| RU95104885A (ru) | 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция | |
| ES2136037A1 (es) | Inhibidores de sulfamida-metaloproteasa | |
| BR9713462A (pt) | Métodos para produção de compostos carotenóides e óleos especiais em sementes de plantas. | |
| UY28878A1 (es) | Compuestos de aril-o heteroarilamida ortosustituidos y composiciones | |
| PE44599A1 (es) | Inhibidores de la enzima acido nitrico sintasa | |
| ES2096329T3 (es) | Procedimiento para la preparacion de derivados del taxano. | |
| AR013494A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| CO5021213A1 (es) | INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8 | |
| ES8106721A1 (es) | Un metodo para la preparacion de derivados de ftalimidina | |
| PE107999A1 (es) | Derivados 3-amidinoanilina, inhibidores del factor x de coagulacion de la sangre activado e intermediarios de los mismos | |
| ES2193874B1 (es) | Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas. | |
| MX9402950A (es) | Piridil-3-carbinoles 4-substituidos herbicidas. | |
| AR009358A1 (es) | Compuesto espirociclico inhibidor de la metaloproteasa | |
| ES2022446B3 (es) | Derivados fenolicos de benzotiazol y su aplicacion como inhibidores de corrosion. | |
| ES2159347T3 (es) | Naftil-acetamidas como inhibidores de spla2. | |
| MX9305364A (es) | Compuestos inhibidores de proteasa retroviral, metodo para su produccion y composicion farmaceutica que los comprende. | |
| CO5011061A1 (es) | Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen | |
| AR018185A1 (es) | Compuestos triciclicos substituidos utiles como inhibidores de la liberacion de acidos grasos mediada por spla2 en mamiferos y uso de dichos compuestos enla fabricacion de composiciones para aliviar los efectos patologicos de enfermedades relacionadas con spla2 | |
| BR0012242A (pt) | Composição de óleo para máquina de refrigeração | |
| MX9304820A (es) | Derivados de 1, 4-benzodioxano, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| ES2183492T3 (es) | Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |